MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.

Akpinar T. S., Hancer V. S., Nalcaci M., Diz-Kucukkaya R.

Turkish journal of haematology : official journal of Turkish Society of Haematology, cilt.30, sa.1, ss.8-12, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.4274/tjh.65807
  • Dergi Adı: Turkish journal of haematology : official journal of Turkish Society of Haematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.8-12
  • Anahtar Kelimeler: MPL W515L/K mutations, JAK-2 V617F mutation, Myeloproliferative neoplasms, Essential thrombocythemia, Primary myelofibrosis, POLYCYTHEMIA-VERA, DISORDERS, JAK2, MYELOFIBROSIS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: The MPL gene encodes the thrombopoietin receptor. Recently MPL mutations (MPL W515L or MPL W515K) were described in patients with essential thrombocythemia (ET) and primary (idiopathic) myelofibrosis (PMF). The prevalence and the clinical importance of these mutations are not clear. In the present study, we aimed to investigate the frequency and clinical significance of MPL W515L/K mutations in our patients with ET and PMF.